Allakos Inc.

Equities

ALLK

US01671P1003

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
1.28 USD -0.78% Intraday chart for Allakos Inc. -2.29% -53.11%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Inflation Worries Continue to Weigh on Mood DJ
Allakos Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Allakos Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Allakos Inc. Announces Publication Highlighting AK006 Mast Cell Inhibition CI
North American Morning Briefing : TSMC Results -2- DJ
Sector Update: Health Care Stocks Slipping Late Afternoon MT
Sector Update: Health Care MT
Top Midday Decliners MT
Allakos Shares Fall After Downgrades by Jefferies, Cantor Fitzgerald, Lifesci Capital MT
JMP Securities Adjusts Allakos' Price Target to $3 From $10, Maintains Market Outperform Rating MT
Barclays Trims Allakos' Price Target to $1 From $1.50, Maintains Underweight Rating MT
Jefferies Downgrades Allakos to Hold From Buy, Adjusts Price Target to $1.50 From $6 MT
Sector Update: Health Care Stocks Weaker Late Afternoon MT
Cantor Fitzgerald Downgrades Allakos to Neutral From Overweight MT
Lifesci Capital Downgrades Allakos to Market Perform From Outperform MT
Sector Update: Health Care Stocks Softer Tuesday Afternoon MT
Sector Update: Health Care MT
Allakos to Cut Workforce in Restructuring After Lirentelimab Trials Fail to Meet Targets; Shares Drop MT
Traders Digest More Bank Earnings, Fueling Narrow Premarket Losses for US Equity Futures MT
Transcript : Allakos Inc. - Special Call
Allakos to stop further development of skin disease drug, plans job cuts RE
Allakos says experimental skin disease drug fails mid-stage studies RE
Allakos Announces Restructuring to Focus on Development of AK006 CI
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints CI
North American Morning Briefing : S&P 500 Eyes -2- DJ
Chart Allakos Inc.
More charts
Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The Company is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
1.28 USD
Average target price
2.9 USD
Spread / Average Target
+126.56%
Consensus
  1. Stock
  2. Equities
  3. Stock Allakos Inc. - Nasdaq
  4. News Allakos Inc.
  5. Allakos : Morgan Stanley Starts Allakos at Equal-Weight With $88 Price Target